Expressive Policy-Based Access Control for Resource-Constrained Devices

Upcoming smart scenarios enabled by the Internet of Things envision smart objects that expose services that can adapt to user behavior or be managed with the goal of achieving higher productivity, often in multi-stakeholder applications. In such environments, smart things are cheap sensors (and actuators) and, therefore, constrained devices. However, they are also critical components because of the importance of the provided information. Therefore, strong security is a must. Nevertheless, existing feasible approaches do not cope well with the principle of least privilege; they lack both expressiveness and the ability to update the policy to be enforced in the sensors. In this paper, we propose an access control model that comprises a policy language that provides dynamic fine-grained policy enforcement in the sensors based on local context conditions. This dynamic policy cycle requires a secure, efficient, and traceable message exchange protocol. For that purpose, a security protocol called Hidra is also proposed. A security and performance evaluation demonstrates the feasibility and adequacy of the proposed protocol and access control model.This work was supported in part by the Training and Research Unit through UPV/EHU under Grant UFI11/16 and in part by the Department of Economic Development and Competitiveness of the Basque Government through the Security Technologies SEKUTEK Collaborative Research Projec

Functional validation of CoQ deficiency fibroblast model with COQ7 mutations

Motivation: Coenzyme Q10 (CoQ10) deficiency syndrome comprises a heterogeneous group of mitochondrial disorders characterized by a decrease in CoQ10 content in cells and tissues. Primary CoQ deficiencies are rare genetic conditions caused by mutations in COQ genes, whose encoded proteins are directly linked to the final biochemical pathway of CoQ biosynthesis. Early diagnosis is both essential and one of the most challenging issues of this disease, mainly due to the variety of associated clinical manifestations. Here we present four clinical cases of primary CoQ10 deficiency, which is presumably caused by COQ7 mutations. The motivation for this work is to validate it in a cellular model based on primary cultures from patients' skin fibroblasts, in order to complete the previously started molecular diagnosis by whole-exome sequencing. Methods: Cultured patients fibroblasts was the biological starting material of our study. CoQ10 levels were measured by HPLC-ECD. In order to study mitochondrial function and respiration, oxygen consumption rate (OCR) was analysed using Seahorse technology. In addition, COQ7, several COQ proteins and other mitochondrial proteins expression were analysed by Western Blotting. Results: Patients' fibroblasts showed a basal level of CoQ10 lower than control fibroblasts (HDF). Moreover, the chromatogram revealed a peak corresponding to DMQ10, which was not seen in HDF. OCR showed mitochondrial respiration was affected in terms of maximal respiration and spare capacity with respect to control cells. Western blot analysis revealed the absence of COQ7 protein in patients' fibroblasts. Moreover, several COQ proteins, which are involved in the CoQ10 biosynthetic pathway, presented a moderate decreased expression. However, several mitochondrial related proteins maintained their physiological levels, such as VDAC, NDUFA9, UQCRCII or mtCOII. Conclusions: CoQ10 deficiency was confirmed in patients' fibroblasts. Since DMQ10 is the substrate of the reaction catalyzed by COQ7 protein, DMQ10 accumulation indicates that the COQ7 reaction is impaired. These results reveal that COQ7 mutation identified in patients' fibroblasts affects protein expression, CoQ10 levels and mitochondrial respiration. Finally, our data support the previous diagnosis obtained by exome analysis, proving that in these clinical cases, the CoQ10 deficiency is being produced by the absence of COQ7 protein

Initiation and Single Dispensing in Cardiovascular and Insulin Medications: Prevalence and Explanatory Factors

: Background: Adherence problems have negative effects on health, but there is little information on the magnitude of non-initiation and single dispensing. Objective: The aim of this study was to estimate the prevalence of non-initiation and single dispensation and identify associated predictive factors for the main treatments prescribed in Primary Care (PC) for cardiovascular disease (CVD) and diabetes. Methods: Cohort study with real-world data. Patients who received a first prescription (2013-2014) for insulins, platelet aggregation inhibitors, angiotensin-converting enzyme inhibitors (ACEI) or statins in Catalan PC were included. The prevalence of non-initiation and single dispensation was calculated. Factors that explained these behaviours were explored. Results: At three months, between 5.7% (ACEI) and 9.1% (antiplatelets) of patients did not initiate their treatment and between 10.6% (statins) and 18.4% (ACEI) filled a single prescription. Body mass index, previous CVD, place of origin and having a substitute prescriber, among others, influenced the risk of non-initiation and single dispensation. Conclusions: The prevalence of non-initiation and single dispensation of CVD medications and insulin prescribed in PC in is high. Patient and health-system factors, such as place of origin and type of prescriber, should be taken into consideration when prescribing new medications for CVD and diabetes

Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients:the SENCOVAC study

BACKGROUND: Chronic kidney disease (CKD) patients are at high-risk for severe Covid-19. The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of SARS-CoV-2 vaccines in CKD patients. Safety and immediate humoral response results are reported here. METHODS: Four cohorts of patients were included: kidney transplant (KT) recipients, haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analyzed. RESULTS: 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (p<0.001). In a multivariate adjusted analysis, absence of an antibody response was independently associated to KT (OR 20.56, p = 0.001) and to BNT162b2 vaccine (OR 6.03, p = 0.023). CONCLUSION: The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%; suggesting that KT patients require persistent isolation measures and booster doses of a Covid-19 vaccine. Potential differences between Covid-19 vaccines should be explored in prospective controlled studies

Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease : A Multicentre Study of Geteccu

Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered "exposed". The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2-2.0), urgent surgery (OR: 1.6; 95% CI: 1.2-2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1-1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3-2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97-1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03-2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

Background: Patients with inflammatory bowel disease who achieve remission with anti-tumour necrosis factor (anti-TNF) drugs may have treatment withdrawn due to safety concerns and cost considerations, but there is a lack of prospective, controlled data investigating this strategy. The primary study aim is to compare the rates of clinical remission at 1?year in patients who discontinue anti-TNF treatment versus those who continue treatment. Methods: This is an ongoing, prospective, double-blind, multicentre, randomized, placebo-controlled study in patients with Crohn?s disease or ulcerative colitis who have achieved clinical remission for ?6?months with an anti-TNF treatment and an immunosuppressant. Patients are being randomized 1:1 to discontinue anti-TNF therapy or continue therapy. Randomization stratifies patients by the type of inflammatory bowel disease and drug (infliximab versus adalimumab) at study inclusion. The primary endpoint of the study is sustained clinical remission at 1?year. Other endpoints include endoscopic and radiological activity, patient-reported outcomes (quality of life, work productivity), safety and predictive factors for relapse. The required sample size is 194 patients. In addition to the main analysis (discontinuation versus continuation), subanalyses will include stratification by type of inflammatory bowel disease, phenotype and previous treatment. Biological samples will be obtained to identify factors predictive of relapse after treatment withdrawal. Results: Enrolment began in 2016, and the study is expected to end in 2020. Conclusions: This study will contribute prospective, controlled data on outcomes and predictors of relapse in patients with inflammatory bowel disease after withdrawal of anti-TNF agents following achievement of clinical remission. Clinical trial reference number: EudraCT 2015-001410-1

Implementación en la UCM del Grado en Estudios Europeos / Bachelor in European Studies en el marco de la alianza europea de universidades UNA EUROPA

El presente proyecto de innovación ha tenido por objetivo la implementación en la Universidad Complutense de Madrid del Nuevo Grado en Estudios Europeos / Bachelor of European Studies (BAES) creado en el marco de la nueva alianza europea de universidades UNA EUROPA integrada por la Universidad Complutense de Madrid, la Universidad de la Sorbona (París – I), Universidad Libre de Berlín, Universidad de Bolonia, Universidad Jaguelónica de Cracovia, Universidad de Helsinki, Universidad Católica de Lovaina, y Universidad de Edimburgo